by FN Qamar · 2024 · Cited by 10 — The efficacy was 93.9% during the first 12 months but declined to 89% by the end of the 46-month surveillance period [15,28]. A TCV immunogenicity sub-study ...

Domein: sciencedirect.com Bekijk meer

A single dose of the typhoid conjugate vaccine, Typbar TCV®, provides lasting efficacy in preventing typhoid fever in children ages 9 months to 12 years old.

Domein: medschool.umaryland.edu Bekijk meer

by VM Vashishtha · Cited by 2 — Our analysis shows that the vaccines are effective, although immunity wanes after five years, especially in children under two. We also offered ...

Domein: pubmed.ncbi.nlm.nih.gov Bekijk meer

A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children.

Domein: ox.ac.uk Bekijk meer

by F Qadri · 2024 · Cited by 11 — A decline in the protection conferred by a single-dose TCV was observed 3–5 years after vaccination, with the greatest decline in protection and ...

Domein: thelancet.com Bekijk meer

by VM Vashishtha · 2025 · Cited by 2 — The analysis revealed that a single dose of TCV exhibited the highest efficacy among WHO-prequalified typhoid vaccines, with a pooled vaccine efficacy of 83% ( ...

Domein: tandfonline.com Bekijk meer

by RE Black · 1990 · Cited by 177 — Vaccine efficacy in the first two years after vaccination was 59% for two doses and 29% for one dose; no efficacy was found 3-5 years after vaccination.

Domein: pubmed.ncbi.nlm.nih.gov Bekijk meer

by FN Qamar · 2024 · Cited by 10 — A high seroconversion was observed at 4-6 weeks after a single dose of TCV. A single dose of TCV provides durable immunogenicity.

Domein: ijidonline.com Bekijk meer

One dose of the conjugate typhoid vaccine has an estimated efficacy of 78.3% in children ages 9 months to 12 years and remained strong over 4 years of follow- ...

Domein: cidrap.umn.edu Bekijk meer

by R Batool · 2024 · Cited by 37 — The pooled efficacy of a single shot of TCV at 2 years post-immunisation was 83% (77–87%; four trials; 111 130 participants; I2 0%; moderate certainty). All ...

Domein: sciencedirect.com Bekijk meer